Agenda 2019


Friday: May 3, 2019

18.30 - 20.00

Welcome Reception

Saturday: May 4, 2019

07.30 - 08.00


08.00 - 08.15

Meeting Registration


Introduction & Meeting Objectives
Alan Burnett & other Co-Chairs

08.30 - 10.30

Session I: Pre-clinical/Genomics 2018: What have we learned about acute leukemia biological mechanisms and how to target them in 2018?

​Chairs: Charles Mullighan & Klaus Metzeler

  • Genomic landscape in ALL; Kathryn Roberts
  • Leukemia cell – microenvironment interactions; Charles Mullighan
  • Clonal hematopoiesis and pre-leukemia – genetics and clinical relevance; Klaus Metzeler
  • Biology and clinical relevance of human AML stem cells; Ravindra Majeti

 Panel discussion – Most promising targets, pathways, and pre-clinical research

10.30 - 11.00

Coffee break

11.00 - 13.00

Session II: Optimization of Standard Treatment in AML

Chairs: Miguel Sanz & Bob Löwenberg

  • Risk-adapted trials for AML: The Spanish CETLAM experience; Jorge Sierra
  • Maintenance therapy with targeted agents and post-transplant; Christoph Röllig
  • Treatment and outcomes of AML in older adults; Richard Larson 
  • Frontline treatments in AML; Bob Löwenberg

Panel Discussion



13.45 - 15.45

Session III: Novel Treatment Strategies in ALL                                                              
Chairs: Dieter Hoelzer & Richard Larson

  • Current status and questions in Adult ALL; Nicola Gökbuget 
  • Oncogenic classification and its contribution in ALL to MRD; Nicolas Boissel 
  • Current indications for allo SCT in ALL in the era of targeted therapies; Dieter Hoelzer
  • Management of older adults with ALL: challenges & current approaches; Anjali Advani
  • Ph+ ALL, what is the best TKI and which patient should be transplanted?; Oliver Ottmann 
  • Diagnostic and treatments strategies for bcr-ABL-like ALL; Sabina Chiaretti

Panel Discussion

15.45 - 17.30

Session IV: Can we truly integrate MRD measurement into clinical practice?          

Chairs: Marion Subklewe & Roland Walter 

  • Risk adapted therapies for primary AML based on genetics and MRD; Adriano Venditti
  • MRD as a prognostic tool; Sylvie Freeman
  • Molecular Minimal Residual Disease Detection in adult AML; Peter Valk

Panel Discussion


2nd iwAL Dinner

Sunday: May 5, 2019

08.00 - 08.30


08.30 - 10.45

Session V: Novel Approaches and Targeted Therapies in AML
Chairs: Richard Stone & Bob Löwenberg

  • Personalized treatment strategies in AML; Torsten Haferlach
  • Liposomal Advances (CPX-351); Richard Stone
  • New Therapies for FLT3+ AML; Mark Levis
  • Targeting IDH1; Stephane de Botton
  • Antibody–drug conjugates; Naval Daver 
  • Update on BCL-2 Inhibitors and Combinations; Andrew Wei
  • Venetoclax-based therapy in first-line treatment of AML; Marina Konopleva
  • Syk-inhibition; Richard Stone
  • HDAC inhibitors: a platform for other combinations; Dan DeAngelo

Panel Discussion

10.45 - 11.00

Coffee break

11.00 - 13.00

Session VI: Immunotherapy of AML & ALL

Chairs: Mark Levis & Dan DeAngelo  

Recent advances in Immunotherapy of AML & ALL

  • Immune checkpoint-based approaches in AML; Ivana Gojo
  • Ph- relapsed or refractory B-cell precursor ALL (Blinatumomab); Nicola Gökbuget
  • CD33 & CD123 bispecific antibodies in AML: clinical updates; Farhad Ravandi
  • Monoclonal antibodies for the treatment of acute leukemia (non-BiTEs); Dan DeAngelo
  • Dendritic cell vaccination; Marion Subklewe
  • MDM2 Inhibition in r/r AML; Giovanni Martinelli

Special Panel discussion: How can new targets be incorporated in the immune era in acute leukemia? (Effective clinical trial design in field of immunotherapy)
Chairs: Alan Burnett + Richard Stone, G Martinelli, Bob Lowenberg, Naval Daver

13.00 - 13.45


13.45 - 16.00

Session VII: CAR-T/Cellular Therapies in AML and ALL Special Session

Chairs: Stephen Gottschalk & Noelle Frey

  • CAR-T 19 and allo SCT in ALL; Noelle Frey
  • Paediatric vs AYA – ALL; Wendy Stock
  • AML for CAR-T – targeting CD123; Marion Subklewe
  • e-break
  • “Off-the-shelf” CAR-T Strategies; TBC
  • Managing toxicities; Bianca Santomasso
  • Immunotherapy with genetically-modified NK cells for leukemia; Stephen Gottschalk 

Panel discussion:


Final Meeting Summary & Conclusions
iwAL Committee



Sheraton Tampa Riverwalk Hotel
200 North Ashley Drive, Tampa,
Florida, 33602 USA

© 2017 - 2019 World Health Communications Ltd / Brandcast Health

Media Partner:

Meeting Organizers: